Nature’s Sunshine announces a secondary stock offering of 2,854,607 shares, solely benefiting Fosun Pharma USA, Inc.
Quiver AI Summary
Nature’s Sunshine Products, Inc. has announced the launch of an underwritten secondary public offering of up to 2,854,607 shares of its common stock, to be sold by Fosun Pharma USA, Inc. The proceeds from this offering will go entirely to the Selling Stockholder, as Nature's Sunshine itself will not sell any shares or receive any proceeds. The company has an arrangement to potentially buy up to $15 million worth of these shares as part of a previously announced share repurchase program, though there is no minimum purchase commitment. D.A. Davidson & Co. is the sole book-running manager for the offering, which is made under a shelf registration statement with the SEC. Investors are advised to review the related documents available on the SEC’s website before considering an investment.
Potential Positives
- Nature’s Sunshine is launching an underwritten secondary public offering, which could signal confidence in the company’s market position and potential for growth.
- The company has the option to repurchase up to $15.0 million of its common stock, showing a commitment to shareholder value and potential price stabilization.
- The offering is conducted under a shelf registration statement that has been recently effective, indicating readiness and compliance with regulatory requirements.
- The company operates in more than 40 countries and manufactures most of its products in-house, ensuring quality and broad market reach, which enhances its reputation in the health and wellness sector.
Potential Negatives
- The company is not receiving any proceeds from the secondary public offering, which may indicate a lack of financial stability or need for capital raising actions.
- There is uncertainty regarding the company's intention to purchase its own shares, as they have not committed to a minimum purchase, potentially leading to investor skepticism about their stock value.
- The mention of risks associated with leadership transition could imply instability or uncertainty about the company's future direction and performance.
FAQ
What is the purpose of the Nature's Sunshine secondary public offering?
The offering aims to sell up to 2,854,607 shares of common stock, primarily benefiting the Selling Stockholder, Fosun Pharma USA, Inc.
Is Nature's Sunshine selling its own shares in this offering?
No, Nature's Sunshine is not selling any shares and will not receive any proceeds from this offering.
Who is managing the Nature's Sunshine stock offering?
D.A. Davidson & Co. is acting as the sole book-running manager for the stock offering.
How can investors access the related documents for the offering?
Investors can obtain the registration documents for free by visiting EDGAR on the SEC's website at www.sec.gov.
What is the maximum amount Nature's Sunshine may repurchase?
The Company may purchase up to $15.0 million of its common stock as part of its share repurchase program.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NATR Hedge Fund Activity
We have seen 30 institutional investors add shares of $NATR stock to their portfolio, and 52 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 136,725 shares (+226.8%) to their portfolio in Q1 2025, for an estimated $1,715,898
- WASATCH ADVISORS LP removed 90,777 shares (-18.9%) from their portfolio in Q1 2025, for an estimated $1,139,251
- TIETON CAPITAL MANAGEMENT, LLC removed 49,542 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $621,752
- MILLENNIUM MANAGEMENT LLC removed 48,703 shares (-62.9%) from their portfolio in Q1 2025, for an estimated $611,222
- JANNEY MONTGOMERY SCOTT LLC added 27,108 shares (+inf%) to their portfolio in Q1 2025, for an estimated $340,205
- MACKENZIE FINANCIAL CORP added 22,855 shares (+inf%) to their portfolio in Q1 2025, for an estimated $286,830
- EXCHANGE TRADED CONCEPTS, LLC removed 22,333 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $327,401
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
LEHI, Utah, June 25, 2025 (GLOBE NEWSWIRE) -- Nature’s Sunshine Products, Inc. (NASDAQ: NATR) (“Nature’s Sunshine” or the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the launch of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the “Selling Stockholder”).
The Selling Stockholder will receive all of the net proceeds from the offering. Nature’s Sunshine is not selling any shares of common stock in the offering and will not receive any proceeds from the offering. The Selling Stockholder will pay any underwriting discounts and commissions and transfer taxes attributable to the resale of the shares of the Company’s common stock the Selling Stockholder holds, as well as certain reasonable out-of-pocket expenses incurred by the underwriter. The Company will bear all other costs, fees and expenses incurred in effecting the registration of the shares in the offering.
As part of the offering, the Company has agreed with the Selling Stockholder that it may purchase up to $15.0 million of the shares of its common stock that are subject to the offering from the underwriters at the public offering price as part of the Company’s previously announced share repurchase program. However, the Company has not agreed to purchase a minimum amount of shares and may determine to purchase fewer or no shares in this offering. Accordingly, there can be no guarantee that the Company will purchase any shares in this offering and investors should not rely on such agreement as evidence that this offering is more likely to be successful. The Company anticipates that the stock repurchase, if any, would be funded from cash on-hand and funds drawn from its credit facility.
D.A. Davidson & Co. is acting as sole book-running manager and representative of the underwriters for the offering.
The common stock is being offered pursuant to a shelf registration statement (which includes a base prospectus) on Form S-3 (File No. 333-287882) that was filed by the Company with the Securities and Exchange Commission (the “SEC”) on June 9, 2025 and became effective on June 18, 2025.
A preliminary prospectus supplement relating to these securities will be filed with the SEC. Before you invest, you should read the registration statement, the base prospectus, the preliminary prospectus supplement, and other documents filed with the SEC and incorporated by reference therein for more complete information about Nature’s Sunshine and this offering. You may obtain these documents free of charge by visiting EDGAR on the SEC's website at www.sec.gov.
The offering is being made only by means of a prospectus and related prospectus supplement, copies of which, when available, may be obtained on the SEC’s website, www.sec.gov, or from D.A. Davidson & Co.,Attention: Syndicate Department, 8 Third Street North, Great Falls, MT 59401, by telephone at (800) 332-5915 and by e-mail: [email protected] .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Nature’s Sunshine Products
Nature’s Sunshine Products (NASDAQ: NATR), a leading natural health and wellness company, markets and distributes nutritional and personal care products in more than 40 countries. Nature’s Sunshine manufactures most of its products through its own state-of-the-art facilities to ensure its products continue to set the standard for the highest quality, safety and efficacy on the market today. Additional information about the company can be obtained at its website, www.naturessunshine.com .
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding the Company’s future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, strategies and financial results, including statements related to the anticipated closing of the offering and the concurrent share repurchase. All statements (other than statements of historical fact) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made in light of our experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, include, but are not limited to the completion of the offering and the concurrent share repurchase, the satisfaction of customary closing conditions related to the offering, the transition of leadership of the Company having a negative effect on the Company’s future business expectations, and the risks associated with searching for a successor President and Chief Executive Officer taking longer than intended or not meeting the Board’s expectations. These and other risks and uncertainties that could cause actual results to differ from predicted results are more fully detailed under the caption “Risk Factors” in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports filed on Form 10-Q. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this press release. Except as is required by law, the Company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this press release.
Investor Relations:
Gateway Group, Inc.
Cody Slach
1-949-574-3860
[email protected]